GCA
RARE icon

Gideon Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Gideon Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,975
Closed -$303K – 484
2018
Q3 		$303K Buy
+3,975
New +$323K 0.14% 241

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Gideon Capital Advisors's RARE Position: Q4 2018 in Review

Gideon Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 3,975 shares — an estimated $303K sold.

Gideon Capital Advisors first reported a position in RARE in Q3 2018 and held it in 1 quarter. The position peaked at $303K in Q3 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Gideon Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 3,975 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $303K.
  • Gideon Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 1 quarter.
  • Gideon Capital Advisors's Ultragenyx Pharmaceutical position peaked at $303K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.